Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GTB-3650 TriKE
- Development stage
- Unknown
- Lead developer
- GT Biopharma
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GTB-3650 TriKE is a second-generation tri-specific killer engager (TriKE) developed by GT Biopharma for the treatment of CD33-positive hematological malignancies, including relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The molecule is a recombinant fusion protein consisting of a camelid-derived nanobody targeting CD16 on natural killer (NK) cells, a single-chain variable fragment (scFv) targeting CD33 on myeloid leukemia cells, and a wild-type human IL-15 linker. This configuration allows the drug to simultaneously bridge NK cells to tumor cells while providing a localized IL-15 signal to promote NK cell proliferation, survival, and enhanced cytolytic activity. As of early 2025, GTB-3650 is in Phase 1 clinical development following IND clearance and the initiation of patient enrollment.
- Other names
- GTB-3650 TriKEGTB3650 TriKEGTB 3650 TriKE
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)FCGR3B (Low affinity immunoglobulin gamma Fc region receptor III-B)CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on GTB-3650 TriKE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GTB-3650 TriKE.